It has been ten days since the 2011 annual meeting of the American Society of Hematology (ASH) came to a close.

Since the meeting started, The Beacon has been providing detailed coverage in the form of discussion forum postings, daily updates, and in-depth articles about key research findings.

In this and The Beacon’s next article about the meeting, however, the per­spective changes a bit.

The focus shifts to the bigger picture — to questions like: “What was the impact of the…

The most recent results of a Phase 2 clinical trial indicate that elotuzumab in combination with Revlimid and dexamethasone is safe and effective in relapsed and refractory multiple myeloma patients.

Dr. Sagar Lonial from the Winship Cancer Institute at the Emory University School of Medicine in Atlanta presented the updated Phase 2 results at the American Society for Hematology (ASH) annual meeting in San Diego on Monday.

The preceding Phase 1 trial of elotuzumab showed that 82 percent of relapsed/refractory myeloma patients had a partial response or better to the drug…

Yesterday was the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, and it was packed full with multiple myeloma-related presentations. Presentations started early in the morning and continued through the afternoon.

The morning presentations about potential new myeloma therapies will be covered in this update, and presentations from the rest of the day will be covered in additional updates.

MLN9708

During the first talk of the day, Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented results from a Phase 1…

Yesterday was the first day of the American Society of Hematology (ASH) 2011 annual meeting, which is being held in San Diego.

Although the day featured no oral presentations of new myeloma-related research, it started with an interesting educational session focused on multiple myeloma.

There also were a number of poster presentations during the day summarizing important new research findings.

The educational session in the morning featured three presentations by leading myeloma specialists.

Induction Therapy And Maintenance Treatment

The first presentation was by Dr. Donna Reece of the Princess Margaret…

Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments.  This review not only described a wide range of potential new myeloma treatments, but also included the experts’ thoughts on where research into new treatments should go in the future.

Given the recent new drug application for carfilzomib and the upcoming annual meeting of the American Society of Hematology — which undoubtedly will host discussions of many potential new myeloma treatments — it seems an appropriate time to go back to the…